

1 October 2024

ASX Announcement

Firebrick Investor Update Webinar Recording

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) held its Investor Update Webinar (ASX announcement 25 September) today.

For those investors and interested parties that were unable to attend the Webinar, you can access a recording on our website at:

https://firebrickpharmabucket.s3.ap-southeast-2.amazonaws.com/wp-content/uploads/2024/10/01202750/firebrick_pharma_investor_update-1080p.mp4

This announcement was authorised by Dr Peter Molloy, Executive Chairman of Firebrick Pharma.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator focused on developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has successfully developed a PVP-I nasal spray (Nasodine® Nasal Spray) and filed international trademarks and multiple patents on the product. The Company has also completed six clinical trials that have affirmed the product's safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Firebrick is now commercialising Nasodine in international markets, with the product already launched in the United States and Singapore.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com